BRPI0614122A8 - composto derivado de quinolina, composição farmacêutica e uso do referido composto - Google Patents

composto derivado de quinolina, composição farmacêutica e uso do referido composto

Info

Publication number
BRPI0614122A8
BRPI0614122A8 BRPI0614122A BRPI0614122A BRPI0614122A8 BR PI0614122 A8 BRPI0614122 A8 BR PI0614122A8 BR PI0614122 A BRPI0614122 A BR PI0614122A BR PI0614122 A BRPI0614122 A BR PI0614122A BR PI0614122 A8 BRPI0614122 A8 BR PI0614122A8
Authority
BR
Brazil
Prior art keywords
compounds
compound
pharmaceutical composition
pharmaceutically acceptable
treatment
Prior art date
Application number
BRPI0614122A
Other languages
English (en)
Inventor
Koul Anil
Francis Alain Lancois David
Thérèse Jeanne Pasquier Elisabeth
Emile Georges Guillemont Jérôme
Jozef Lodewijk Marcel Andries Koenraad
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0614122A2 publication Critical patent/BRPI0614122A2/pt
Publication of BRPI0614122A8 publication Critical patent/BRPI0614122A8/pt
Publication of BRPI0614122B1 publication Critical patent/BRPI0614122B1/pt
Publication of BRPI0614122B8 publication Critical patent/BRPI0614122B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)

Abstract

composto derivado de quinolina, composição farmacêutica e uso do referido composto. a presente invenção se refere a novos derivados de quinolina substituidos, de acordo com as fórmulas gerais (1a) ou (1b): a um sal de adição de ácido ou de base farmaceuticamente aceitável do mesmo, uma amina quaternária do mesmo, uma forma estereoquimicamente isomérica do mesmo, uma forma tautomérica do mesmo, uma forma de n-óxido do mesmo ou um pró-fármaco do mesmo. os compostos reivindicados são de utilidade no tratamento de uma doença bacteriana, particularmente, as doenças provocadas pela micobactéria patogênica, tal como, mycobacterium tuberculosis, m. bovis, m. avium e m. marinum. também é reivindicada uma composição que compreende um veículo farmaceuticamente aceitável e, como ingrediente ativo, uma quantidade terapeuticamente eficaz dos compostos reivindicados, o uso dos compostos ou das composições reivindicadas para a fabricação de um medicamento destinado ao tratamento de doenças bacterianas e um processo para a preparação dos compostos reivindicados.
BRPI0614122A 2005-07-28 2006-07-26 composto derivado de quinolina, composição farmacêutica e uso do referido composto BRPI0614122B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05106962 2005-07-28
EP05106962.3 2005-07-28
PCT/EP2006/064656 WO2007014885A1 (en) 2005-07-28 2006-07-26 Antibacterial quinoline derivatives

Publications (4)

Publication Number Publication Date
BRPI0614122A2 BRPI0614122A2 (pt) 2011-03-09
BRPI0614122A8 true BRPI0614122A8 (pt) 2019-01-29
BRPI0614122B1 BRPI0614122B1 (pt) 2020-09-24
BRPI0614122B8 BRPI0614122B8 (pt) 2023-01-10

Family

ID=35610159

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0614122A BRPI0614122B8 (pt) 2005-07-28 2006-07-26 composto derivado de quinolina, composição farmacêutica e uso do referido composto

Country Status (31)

Country Link
US (1) US7915292B2 (pt)
EP (1) EP1912948B1 (pt)
JP (1) JP5100647B2 (pt)
KR (1) KR101334719B1 (pt)
CN (1) CN101273016B (pt)
AP (1) AP2322A (pt)
AR (1) AR054587A1 (pt)
AU (1) AU2006274918B2 (pt)
BR (1) BRPI0614122B8 (pt)
CA (1) CA2614981C (pt)
CY (1) CY1117247T1 (pt)
DK (1) DK1912948T3 (pt)
EA (1) EA015617B1 (pt)
ES (1) ES2554924T3 (pt)
HK (1) HK1122804A1 (pt)
HR (1) HRP20151308T1 (pt)
HU (1) HUE026259T2 (pt)
IL (1) IL188987A0 (pt)
JO (1) JO3077B1 (pt)
MX (1) MX2008001219A (pt)
MY (1) MY148219A (pt)
NO (1) NO341795B1 (pt)
NZ (1) NZ565946A (pt)
PL (1) PL1912948T3 (pt)
PT (1) PT1912948E (pt)
RS (1) RS54382B1 (pt)
SI (1) SI1912948T1 (pt)
TW (1) TWI427065B (pt)
UA (1) UA94051C2 (pt)
WO (1) WO2007014885A1 (pt)
ZA (1) ZA200800783B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080076924A1 (en) * 2006-06-30 2008-03-27 Patrick Betschmann Piperazines as P2X7 antagonists
BR112012029139A2 (pt) * 2010-05-21 2019-09-24 Syngenta Participations Ag amidas como fungicidas
EA038350B1 (ru) 2012-04-27 2021-08-12 Янссен Фармацевтика Нв Антибактериальные хинолиновые производные
ES2576491T3 (es) 2012-04-27 2016-07-07 Janssen Pharmaceutica, N.V. Derivados de quinolina antibacterianos
RU2648247C2 (ru) * 2012-08-24 2018-03-23 Ф. Хоффманн-Ля Рош Аг Бициклические производные пиридина, полезные в качестве ингибитора белков, связывающих жирные кислоты (FABP) 4 и/или 5
CN104650054B (zh) * 2013-11-25 2019-09-13 重庆医药工业研究院有限责任公司 一种抗结核菌的喹啉噻吩芳氧乙胺衍生物
CN105175329B (zh) * 2014-06-10 2017-09-19 重庆圣华曦药业股份有限公司 一种贝达喹啉消旋体的合成路线及方法
US20190321324A1 (en) * 2016-12-30 2019-10-24 Board Of Regents, The University Of Texas System Quaternary amine antibiotic therapeutics
CN110804016B (zh) * 2019-12-05 2022-11-04 福建省微生物研究所 抗结核分枝杆菌的二芳基喹啉衍生物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1041035A3 (ru) * 1982-02-25 1983-09-07 Киорин Сейяку Кабусики Кайся (Фирма) Способ получени производных хинолинкарбоновой кислоты,их гидратов или солей
JPS6463518A (en) * 1987-09-02 1989-03-09 Otsuka Pharma Co Ltd Antiarrhythmic agent
US5235054A (en) * 1992-07-15 1993-08-10 Pfizer Inc. 3-carboxaldehyde substituted quinolines and naphthyridines
PT760819E (pt) * 1994-05-24 2000-11-30 Hoffmann La Roche Derivado dicarbonilicos triciclicos
US6320051B1 (en) * 1998-04-29 2001-11-20 Smithkline Beecham Plc Quinolones used as MRS inhibitors and bactericides
PL222801B1 (pl) 2002-07-25 2016-09-30 Janssen Pharmaceutica Nv Pochodne chinoliny, ich zastosowanie, sposób ich wytwarzania oraz kompozycja farmaceutyczna zawierająca je

Also Published As

Publication number Publication date
AR054587A1 (es) 2007-06-27
UA94051C2 (ru) 2011-04-11
KR101334719B1 (ko) 2013-11-29
DK1912948T3 (en) 2016-01-18
IL188987A0 (en) 2008-08-07
CA2614981A1 (en) 2007-02-08
PL1912948T3 (pl) 2016-02-29
HRP20151308T1 (hr) 2016-01-01
BRPI0614122A2 (pt) 2011-03-09
KR20080031973A (ko) 2008-04-11
NZ565946A (en) 2010-11-26
NO20081008L (no) 2008-02-27
EP1912948B1 (en) 2015-09-09
BRPI0614122B8 (pt) 2023-01-10
JO3077B1 (ar) 2017-03-15
RS54382B1 (en) 2016-04-28
EA200800455A1 (ru) 2008-10-30
AU2006274918B2 (en) 2011-09-22
MX2008001219A (es) 2008-03-24
JP2009502869A (ja) 2009-01-29
ES2554924T3 (es) 2015-12-28
US7915292B2 (en) 2011-03-29
TWI427065B (zh) 2014-02-21
NO341795B1 (no) 2018-01-22
US20080182855A1 (en) 2008-07-31
PT1912948E (pt) 2015-12-21
WO2007014885A1 (en) 2007-02-08
CY1117247T1 (el) 2017-04-05
CN101273016A (zh) 2008-09-24
CA2614981C (en) 2014-06-03
AP2322A (en) 2011-11-18
JP5100647B2 (ja) 2012-12-19
CN101273016B (zh) 2013-01-02
EP1912948A1 (en) 2008-04-23
ZA200800783B (en) 2009-06-24
SI1912948T1 (sl) 2016-01-29
HUE026259T2 (en) 2016-06-28
TW200800901A (en) 2008-01-01
EA015617B1 (ru) 2011-10-31
HK1122804A1 (en) 2009-05-29
BRPI0614122B1 (pt) 2020-09-24
AU2006274918A1 (en) 2007-02-08
MY148219A (en) 2013-03-29

Similar Documents

Publication Publication Date Title
BRPI0614122A8 (pt) composto derivado de quinolina, composição farmacêutica e uso do referido composto
BRPI0720220B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo
EA200602260A1 (ru) Применение замещенных хинолиновых производных для лечения заболеваний, вызываемых микобактериями, резистентными к лекарственным средствам
BRPI0312927B8 (pt) "compostos, derivados de quinolina, composição, seu uso como inibidores micobacteriais, bem como processo para preparação dos referidos derivados".
BRPI0719920B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, seu processo de preparação, combinação e produto compreendendo o mesmo e composto intermediário
BR112022000782A2 (pt) Composto, composição farmacêutica, processo para preparar um composto, composto intermediário, e, uso de um composto, ou de um sal farmaceuticamente aceitável ou solvato do mesmo, ou de uma composição farmacêutica
CY1112230T1 (el) Αντιβακτηριακα παραγωγα κινολινης
ZA202203107B (en) Azaindole carboxamide compounds for the treatment of mycobacterial infections
CY1114384T1 (el) Αντιβακτηριακα παραγωγα κινολινης
MX2014013056A (es) Derivados de quinolina antibacterianos.
BRPI0612534B8 (pt) uso de um composto derivado de quinolina, o referido composto, sua combinação, composição farmacêutica, uso da referida combinação, e produto
BRPI0720251B8 (pt) derivado de quinolina, sua composição farmacêutica, seu uso, combinação e produto compreendendo o mesmo
CY1112027T1 (el) Αντιβακτηριακα παραγωγα κινολινης
MX2014013055A (es) Derivados de quinolina antibacterianos.
TH102419A (th) อนุพันธ์ควิโนลีนต่อต้านแบคทีเรีย

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/09/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/07/2006 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2594 DE 24/09/2020 QUANTO AO INVENTOR POR ERRO MATERIAL DO TITULAR.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.